Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Sentinel vascular access monitoring after endovascular intervention predicts access outcome.

Kumbar L, Peterson E, Zaborowicz M, Besarab A, Yee J, Zasuwa G.

J Vasc Access. 2018 Nov 27:1129729818812729. doi: 10.1177/1129729818812729. [Epub ahead of print]

PMID:
30477378
2.

How arteriovenous grafts could help to optimize vascular access management.

Besarab A, Kumbar L.

Semin Dial. 2018 Nov;31(6):619-624. doi: 10.1111/sdi.12718. Epub 2018 Jun 1.

PMID:
29856898
3.

Characteristics of enzyme-linked immunosorbent assay for detection of IgG antibodies specific to Сhlamydia trachomatis heat shock protein (HSP-60)

Galkin OY, Besarab AB, Lutsenko TN.

Ukr Biochem J. 2017 Jan-Feb;89(1):22-30. doi: 10.15407/ubj89.01.022.

PMID:
29236386
4.

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH.

Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011.

5.
6.

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB.

Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-91. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19.

7.

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB.

Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2.

8.

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.

Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB.

J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22.

9.

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.

Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB.

Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3.

10.

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.

Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A.

Kidney Int. 2015 Nov;88(5):1187-94. doi: 10.1038/ki.2015.203. Epub 2015 Jul 8.

11.

Vascular access cannulation practices and outcomes.

Besarab A, Kumbar L.

Kidney Int. 2014 Oct;86(4):671-3. doi: 10.1038/ki.2014.158.

12.
13.

Uses and interpretation of iron studies in patients on chronic dialysis.

Besarab A, Szczech L.

Semin Dial. 2014 Nov-Dec;27(6):579-81. doi: 10.1111/sdi.12261. Epub 2014 Jul 1. No abstract available.

PMID:
24980979
14.

Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.

Moore CL, Besarab A, Ajluni M, Soi V, Peterson EL, Johnson LE, Zervos MJ, Adams E, Yee J.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1232-9. doi: 10.2215/CJN.11291113. Epub 2014 Jun 26.

15.

Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?

Besarab A.

Nephrol News Issues. 2014 Feb;28(2):12, 14-5. Review. No abstract available.

PMID:
24649747
16.

Lifting the veil: insights into vascular access options.

Kumbar L, Besarab A.

Clin J Am Soc Nephrol. 2013 May;8(5):708-10. doi: 10.2215/CJN.03070313. Epub 2013 Apr 18. No abstract available.

17.

Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy.

Yessayan L, Sandhu A, Besarab A, Yessayan A, Frinak S, Zasuwa G, Yee J.

Int J Nephrol. 2013;2013:703038. doi: 10.1155/2013/703038. Epub 2013 Mar 18.

18.

Peginesatide in patients with anemia undergoing hemodialysis.

Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A; EMERALD Study Groups.

N Engl J Med. 2013 Jan 24;368(4):307-19. doi: 10.1056/NEJMoa1203165.

19.

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM.

BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.

20.

The normal HCT trial re-revisited: what were the actual findings?

Besarab A, Bolton WK, Nissenson AR, Schwab SJ.

Kidney Int. 2012 Jul;82(2):242; author reply 242-3. doi: 10.1038/ki.2012.204. No abstract available.

21.

Academic interventional nephrology: a model for training, research, and patient care.

Roy-Chaudhury P, Yevzlin A, Bonventre JV, Agarwal A, Almehmi A, Besarab A, Dwyer A, Hentschel DM, Kraus M, Maya I, Pflederer T, Schon D, Wu S, Work J.

Clin J Am Soc Nephrol. 2012 Mar;7(3):521-4. doi: 10.2215/CJN.08360811. Epub 2012 Feb 16. Review.

22.

Surveillance and monitoring of dialysis access.

Kumbar L, Karim J, Besarab A.

Int J Nephrol. 2012;2012:649735. doi: 10.1155/2012/649735. Epub 2011 Nov 22.

23.

Anemia and iron management.

Besarab A.

Semin Dial. 2011 Sep-Oct;24(5):498-503. doi: 10.1111/j.1525-139X.2011.00983.x. Epub 2011 Sep 9. No abstract available.

PMID:
21906169
24.

De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach.

Chalhoub E, Frinak S, Zasuwa G, Faber MD, Peterson E, Besarab A, Yee J.

Clin Nephrol. 2011 Jul;76(1):1-8.

PMID:
21722599
25.

Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.

Schiller B, Besarab A.

Curr Med Res Opin. 2011 Aug;27(8):1539-50. doi: 10.1185/03007995.2011.588202. Epub 2011 Jun 17. Review.

PMID:
21682552
26.

Dialysis: Two for the price of one: is rt-PA ready for prime time?

Besarab A, Moore CL.

Nat Rev Nephrol. 2011 Jun;7(6):310-1. doi: 10.1038/nrneph.2011.54. No abstract available.

PMID:
21625208
27.

Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.

Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB.

Drug Des Devel Ther. 2011 Mar 14;5:147-53. doi: 10.2147/DDDT.S17521.

28.

Candidate biomarkers for erythropoietin response in end-stage renal disease.

Besarab A, Yee J.

Kidney Int. 2011 Mar;79(5):488-90. doi: 10.1038/ki.2010.479.

29.

Catheter management in hemodialysis patients: delivering adequate flow.

Besarab A, Pandey R.

Clin J Am Soc Nephrol. 2011 Jan;6(1):227-34. doi: 10.2215/CJN.04840610. Epub 2010 Nov 29. Review.

30.

Iron supplementation to treat anemia in patients with chronic kidney disease.

Besarab A, Coyne DW.

Nat Rev Nephrol. 2010 Dec;6(12):699-710. doi: 10.1038/nrneph.2010.139. Epub 2010 Oct 19. Review. Erratum in: Nat Rev Nephrol. 2012 Feb;8(2):63.

PMID:
20956992
31.

Automated intravascular access pressure surveillance reduces thrombosis rates.

Zasuwa G, Frinak S, Besarab A, Peterson E, Yee J.

Semin Dial. 2010 Sep-Oct;23(5):527-35. doi: 10.1111/j.1525-139X.2010.00755.x. Epub 2010 Aug 13.

PMID:
20723160
32.

Which direction is right for vascular access surveillance? A debate.

Abreo K, Allon M, Asif A, Atray N, Besarab A, Dember LM, Dixon BS, DeVita M, Kaufman J, Murray BM, Nguyen VD, Paulson WD, Ram SJ, Vachharajani T, Vesely TM, White JJ, Work J, Kennedy J.

Nephrol News Issues. 2010 Jun;24(7):30, 32, 34. No abstract available.

PMID:
20617629
33.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.

Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC; PATRONUS Investigators.

Nephrol Dial Transplant. 2010 Dec;25(12):4009-17. doi: 10.1093/ndt/gfq305. Epub 2010 Jun 3.

34.

Managing anemia in patients with chronic heart failure: what do we know?

Sandhu A, Soman S, Hudson M, Besarab A.

Vasc Health Risk Manag. 2010 Apr 15;6:237-52.

35.

Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome.

Besarab A, Hörl WH, Silverberg D.

Oncologist. 2009;14 Suppl 1:22-33. doi: 10.1634/theoncologist.2009-S1-22. Review.

36.

Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections.

Rabindranath KS, Bansal T, Adams J, Das R, Shail R, MacLeod AM, Moore C, Besarab A.

Nephrol Dial Transplant. 2009 Dec;24(12):3763-74. doi: 10.1093/ndt/gfp327. Epub 2009 Jul 10. Review.

PMID:
19592599
37.

Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality.

Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Ureña P, Iñigo P, Minutolo R, Haviv YS, Yeates K, Agüera ML, MacRae JM, Levin A.

Clin J Am Soc Nephrol. 2009 Jul;4(7):1176-82. doi: 10.2215/CJN.04920908. Epub 2009 May 7.

38.

What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?

Besarab A, Frinak S, Yee J.

Adv Chronic Kidney Dis. 2009 Mar;16(2):131-42. doi: 10.1053/j.ackd.2008.12.007. Review.

PMID:
19233072
39.

Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?

Yee J, Zasuwa G, Frinak S, Besarab A.

Adv Chronic Kidney Dis. 2009 Mar;16(2):83-93. doi: 10.1053/j.ackd.2008.12.003. Review.

PMID:
19233067
40.

The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access.

Sidawy AN, Spergel LM, Besarab A, Allon M, Jennings WC, Padberg FT Jr, Murad MH, Montori VM, O'Hare AM, Calligaro KD, Macsata RA, Lumsden AB, Ascher E; Society for Vascular Surgery.

J Vasc Surg. 2008 Nov;48(5 Suppl):2S-25S. doi: 10.1016/j.jvs.2008.08.042. Review.

42.

Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Pro.

Besarab A.

J Am Soc Nephrol. 2008 Sep;19(9):1629-31. doi: 10.1681/ASN.2008020172. Epub 2008 May 28.

43.

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16.

44.

New developments in anemia management in chronic kidney disease.

Amerling R, Besarab A, Roy C.

Nephrol News Issues. 2008 Mar;22(3):suppl 1-8. Review. No abstract available.

PMID:
18372676
45.

The normal hematocrit study--follow-up.

Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors.

N Engl J Med. 2008 Jan 24;358(4):433-4. doi: 10.1056/NEJMc076523. No abstract available.

PMID:
18216370
46.

The native arteriovenous fistula in 2007. Research needs.

Besarab A, Ravani P, Spergel LM, Roy-Chaudhury P, Asif A.

J Nephrol. 2007 Nov-Dec;20(6):668-73.

PMID:
18046668
47.

The native arteriovenous fistula in 2007. Surveillance and monitoring.

Besarab A, Asif A, Roy-Chaudhury P, Spergel LM, Ravani P.

J Nephrol. 2007 Nov-Dec;20(6):656-67. Review.

PMID:
18046667
48.

Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.

Am J Kidney Dis. 2007 Dec;50(6):989-1000.

PMID:
18037099
49.

Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.

Fishbane S, Besarab A.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1274-82. Epub 2007 Oct 17. Review.

50.

Interventional nephrology: from episodic to coordinated vascular access care.

Asif A, Besarab A, Roy-Chaudhury P, Spergel LM, Ravani P.

J Nephrol. 2007 Jul-Aug;20(4):399-405.

PMID:
17879204

Supplemental Content

Loading ...
Support Center